- Home
- PRQR vs ALDX Comparison
PRQR vs ALDX Comparison
Compare PRQR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- ALDX
- Stock Information
- Founded
- PRQR 2012
- ALDX 2004
- Country
- PRQR Netherlands
- ALDX United States
- Employees
- PRQR N/A
- ALDX N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- ALDX Health Care
- Exchange
- PRQR Nasdaq
- ALDX Nasdaq
- Market Cap
- PRQR 309.5M
- ALDX 304.9M
- IPO Year
- PRQR 2014
- ALDX 2014
- Fundamental
- Price
- PRQR $1.65
- ALDX $6.58
- Analyst Decision
- PRQR Strong Buy
- ALDX Strong Buy
- Analyst Count
- PRQR 6
- ALDX 2
- Target Price
- PRQR $8.50
- ALDX $10.00
- AVG Volume (30 Days)
- PRQR 448.8K
- ALDX 666.8K
- Earning Date
- PRQR 03-13-2025
- ALDX 05-01-2025
- Dividend Yield
- PRQR N/A
- ALDX N/A
- EPS Growth
- PRQR N/A
- ALDX N/A
- EPS
- PRQR N/A
- ALDX N/A
- Revenue
- PRQR $20,235,014.00
- ALDX N/A
- Revenue This Year
- PRQR $39.44
- ALDX N/A
- Revenue Next Year
- PRQR N/A
- ALDX N/A
- P/E Ratio
- PRQR N/A
- ALDX N/A
- Revenue Growth
- PRQR 196.41
- ALDX N/A
- 52 Week Low
- PRQR $1.59
- ALDX $2.75
- 52 Week High
- PRQR $4.62
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- PRQR 28.26
- ALDX 53.63
- Support Level
- PRQR $1.78
- ALDX $6.22
- Resistance Level
- PRQR $1.87
- ALDX $6.87
- Average True Range (ATR)
- PRQR 0.11
- ALDX 0.46
- MACD
- PRQR -0.02
- ALDX -0.03
- Stochastic Oscillator
- PRQR 10.53
- ALDX 60.51
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.